Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2025 08:00 ET | Source: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals Announces First Patient Randomized in FORTITUDE-HCM Phase 2b Clinical Trial Evaluating Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy

Imbria Pharmaceuticals announces first patient randomized in Phase 2b FORTITUDE-HCM trial of ninerafaxstat for non-obstructive hypertrophic cardiomyopathy.
September 16, 2025 08:00 ET | Source: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals Strengthens Leadership with New Board and Key Clinical Appointments

Imbria Pharmaceuticals Strengthens Leadership, Appoints Dr. Cheruvu as Board Chair; James Januzzi, MD, as Senior Research Advisor and SAB Chair.
September 15, 2022 08:00 ET | Source: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals to Participate in the UBS Biotechnology Private Company Virtual Symposium

BOSTON, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
August 22, 2022 08:00 ET | Source: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals to Present Phase 2a Data from the Ninerafaxstat Program at the European Society of Cardiology Congress 2022

BOSTON, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardio-metabolic company developing novel therapies designed to enhance cellular energetics, today...